Quarterly report pursuant to Section 13 or 15(d)

Related Parties

v3.22.2
Related Parties
6 Months Ended
Jun. 30, 2022
Related Parties  
Related Parties

7Related Parties

The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member became the Company’s Chief Medical Officer (“CMO”) effective January 1, 2021. The Company has and will continue to contract the services of the CMO’s spouse through the firm to perform certain activities in connection with the Company’s ongoing clinical trial in FM. During the three and six months ended June 30, 2022 and 2021, the Company paid Gendreau $103,389 and $188,937, respectively, and $77,816 and $142,282, respectively, and had accounts payable of $33,190 and $24,840 to Gendreau as of June 30, 2022 and December 31, 2021, respectively.